Talis Biomedical Corporation
TLIS
$1.60
-$0.08-4.76%
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -85.69% | -65.21% | -55.65% | -59.43% | -41.01% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -85.69% | -65.21% | -55.65% | -59.43% | -41.01% |
| Cost of Revenue | -66.24% | -57.19% | -48.58% | -36.15% | -29.24% |
| Gross Profit | 65.28% | 56.85% | 48.12% | 34.43% | 28.54% |
| SG&A Expenses | 4.25% | -9.84% | -24.03% | -31.80% | -37.60% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -43.54% | -42.29% | -40.74% | -34.63% | -32.17% |
| Operating Income | 42.15% | 41.62% | 40.10% | 33.46% | 31.83% |
| Income Before Tax | 40.54% | 41.50% | 45.13% | 34.22% | 32.50% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 40.54% | 41.50% | 45.13% | 34.22% | 32.50% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 40.54% | 41.50% | 45.13% | 34.22% | 32.50% |
| EBIT | 42.15% | 41.62% | 40.10% | 33.46% | 31.83% |
| EBITDA | 37.39% | 36.91% | 35.70% | 33.46% | 36.74% |
| EPS Basic | 40.91% | 41.95% | 45.88% | 32.34% | 31.65% |
| Normalized Basic EPS | 44.33% | 44.97% | 44.13% | 35.56% | 34.51% |
| EPS Diluted | 40.91% | 41.95% | 45.88% | 32.34% | 31.65% |
| Normalized Diluted EPS | 44.33% | 44.97% | 44.13% | 35.56% | 34.51% |
| Average Basic Shares Outstanding | 0.58% | 0.75% | 1.30% | -3.47% | -2.64% |
| Average Diluted Shares Outstanding | 0.58% | 0.75% | 1.30% | -3.47% | -2.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
